Linezolid versus vancomycin in the treatment of skin and soft tissue infections:meta-analysis of randomised controlled trials

Lin Zhi-qing,Huang Yan-ling,Huang ping,Chen qi

DOI: https://doi.org/10.13461/j.cnki.cja.004691

2010-01-01

Abstract:Objective A meta-analysis of randomized controlled trials on the efficacy and safety in patients with skin and soft tissue infections caused by Gram-positive infections treated with linezolid versus with vancomycin.Methods The data were collected from the Medline database,Embase database,Ovid database,the Cochrane library,and Chinese Biomedical Database,and the references of eligible studies were manually screened.Randomized controlled trials published in the English and Chinese literature comparing linezolid with vancomycin in patients with skin and soft tissue infections caused by Gram-positive infections were eligible for inclusion.Two investigators independently assessed the quality and extracted the data.The methodological quality of trails was assessed by the Jadad-scale plus allocation concealment.Heterogeneity was examined by Chi-square test.Fixed effects model or random effects model were used to pool the data.Sensitivity analyses were used in the treatment course.Results Six randomized controlled studies comparing linezolid with vancomycin were analyzed,focusing on the 1656 patients with skin and soft tissue infections caused by Gram-positive infections.It was found by meta-analysis that,with respect to clinical treatment success,linezolid was more effective than vancomycin in clinically evaluation patients at the end-of-treatment visit[OR 3.78,95% CI(1.18,12.08),P=0.02]and at the test-of-cure visit[OR 2.15,95% CI(1.46,3.17),P=0.0001],however,there was no difference in intention-to-treat patients at the test-of-cure visit[OR 1.37,95% CI(0.98,1.92),P=0.07].With respect to microbiological treatment success,linezolid was more effective than vancomycin in microbiologically evaluation patients at the test-of-cure visit[OR 2.32,95% CI(1.42,3.79),P=0.0008].Additionally,empirical treatment with linezolid was associated with increased eradication rates for S.aureus strains[OR=2.73,95% CI(1.82,4.09),P<0.00001]and MRSA strains[OR=4.00,95% CI(2.31,6.93),P<0.00001] in comparison with vancomycin in microbiologically evaluation patients at the test-of-cure visit,but there was no difference in eradication rates for streptococcal species [OR=1.17,95% CI(0.23,5.97),P=0.85] and enterococcal species [OR=6.43,95% CI(0.23,181.82),P=0.28].Conclusion Linezolid is more effective than vancomycin or equal to vancomycin for treatment of patients with skin and soft tissue infections caused by Gram-positive infections although rigorously designed large sample size randomized double blind clinical trials are required to further demonstrate and support the conclusion.